Home Page: Biology of Blood and Marrow Transplantation

Time 2020-11-04 08:03:59

Web Name: Home Page: Biology of Blood and Marrow Transplantation

WebSite: http://www.bbmt.org

ID:104438

Keywords:

Biology,of,Home,

Description:

Issue Highlights Challenging and Practical Aspects of Nutrition in Chronic Graft-versus-Host DiseaseAndrea Z. Pereira, Sandra Elisa Adami Gonçalves, Morgani Rodrigues, Nelson Hamerschlak, Mary E. FlowersDOI: https://doi.org/10.1016/j.bbmt.2020.08.004Biology of Blood and Marrow Transplantation, Vol. 26, Issue 11PreviewFull-Text HTMLPDFSupplemental MaterialsxChronic graft-versus-host disease (GVHD) occurs in 30% to 70% of allogeneic stem cell transplantation recipients and represents a major cause of morbidity and late mortality [1,2]. Chronic GVHD is a syndrome that can affect the skin, mouth, eye, muscle, fascia, joints, gastrointestinal tract, liver and lungs resembling autoimmune and other immunologic disorders such as scleroderma, Sjögren's syndrome, primary biliary cirrhosis, bronchiolitis obliterans, or immune cytopenia [1,2].Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell TransplantationGina Jiang, Jose-Mario Capo-Chichi, Aijun Liu, Eshetu G. Atenafu, Rajat Kumar, Mark D. Minden, Hong ChangDOI: https://doi.org/10.1016/j.bbmt.2020.07.017Biology of Blood and Marrow Transplantation, Vol. 26, Issue 11PreviewFull-Text HTMLPDFSupplemental MaterialsxAcute myelogenous leukemia (AML), the most common form of adult leukemia, is a highly heterogeneous group of biologically and clinically distinct malignancies characterized by abnormal proliferation of immature myeloid cells [1-3]. Normal karyotype AML (NK-AML) represents the largest subgroup, accounting for 40% to 50% of all cases [1-8]. NK-AML patients are typically classified in an intermediate risk category, although they display different outcomes following curative intent therapy [1-7]. Novel biomarkers are commonly used to further refine predicted outcomes in NK-AML; these include truncating mutations at hotspot residues of Nucleophosmin 1 (NPM1mut) and the allelic ratio (AR) of internal tandem duplication within fms-like tyrosine kinase 3 (FLT3-ITD) [9,10].Baseline Gut Microbiota Composition Is Associated with Major Infections Early after Hematopoietic Cell TransplantationHemant S. Murthy, Raad Z. Gharaibeh, Zeina Al-Mansour, Andrew Kozlov, Gaurav Trikha, Rachel C. Newsome, Josee Gauthier, Nosha Farhadfar, Yu Wang, Debra Lynch Kelly, John Lybarger, Christian Jobin, Gary P. Wang, John R. WingardDOI: https://doi.org/10.1016/j.bbmt.2020.07.023Biology of Blood and Marrow Transplantation, Vol. 26, Issue 11PreviewFull-Text HTMLPDFSupplemental MaterialsxHematopoietic cell transplantation (HCT) provides a curative option for patients with hematologic malignancies. Febrile neutropenia (FN) is common early after HCT, and infections by various enteric and nonenteric pathogens pose a serious threat to survival following HCT. Although an infectious etiology is identified in only 20% to 30% of cases [1,2], empiric gram-negative targeted antibiotic treatment of febrile neutropenia is recommended and has been shown to reduce mortality related to infectious complications [3,4]. Improving Hematopoietic Stem Cell Transplant in the Elderly: Can We Finally Start to Impact Nonrelapse Mortality?Thomas G. KnightDOI: https://doi.org/10.1016/j.bbmt.2020.10.013Publication stage: In Press Corrected ProofPreviewFull-Text HTMLPDFxThe role of allogeneic hematopoietic cell transplant (HCT) in the treatment of older patients with hematologic malignancies has rapidly evolved over the past 2 decades. Historically, older patients were not offered HCT despite being both disproportionally affected by hematologic malignancies and having a higher propensity for higher risk/more aggressive disease. In fact, it was estimated as recently as 2011 that only 6% of patients with acute myelogenous leukemia (AML) older than 60 years in the United States underwent stem cell transplantation [1].Prophylactic foscarnet for human herpesvirus 6: effect on hematopoietic engraftment after reduced intensity conditioning umbilical cord blood transplantationNajla El Jurdi, John Rogosheske, Todd DeFor, Nelli Bejanyan, Mukta Arora, Veronika Bachanova, Brian Betts, Fiona He, Shernan Holtan, Murali Janakiram, Samantha Larson, Joseph Maakaron, Armin Rashidi, Erica Warlick, John E. Wagner, Jo-Anne H Young, Daniel Weisdorf, Claudio G. BrunsteinDOI: https://doi.org/10.1016/j.bbmt.2020.10.008Publication stage: In Press Journal Pre-ProofPreviewFull-Text HTMLPDFxUmbilical cord blood (UCB) is a valuable alternative for allogeneic hematopoietic stem cell transplantation (HCT). However, delayed engraftment, graft failure, and increased risk for opportunistic infections remain major challenges when considering this donor source. Human herpesvirus-6 (HHV-6) reactivation occurs in the majority of UCB recipients.1-3 Thus, UCB recipients are a particularly vulnerable population for HHV-6 viremia and post-transplant complications with severe sequelae such as delayed hematopoietic recovery, graft failure, and limbic encephalitis.Specific Class I HLA Supertypes but Not HLA Zygosity or Expression Are Associated with Outcomes following HLA-Matched Allogeneic Hematopoietic Cell Transplant: HLA Supertypes Impact Allogeneic HCT OutcomesChristine Camacho-Bydume, Tao Wang, Jennifer A. Sees, Marcelo Fernandez-Viña, Muhammad Bilal Abid, Medhat Askar, Amer Beitinjaneh, Valerie Brown, Paul Castillo, Saurabh Chharbra, Shahinaz M. Gadalla, Jing-Mei Hsu, Malek Kamoun, Aleksandr Lazaryan, Taiga Nishihori, Kristin Page, Johannes Schetelig, Katharina Fleischhauer, Steven G.E. Marsh, Sophie Paczesny, Stephen R. Spellman, Stephanie J. Lee, Katharine C. HsuDOI: https://doi.org/10.1016/j.bbmt.2020.10.010Publication stage: In Press Uncorrected ProofPreviewFull-Text HTMLPDFSupplemental MaterialsxEliciting an adaptive immune response against infection or malignancy requires precise interaction of T cell receptors on cytotoxic T lymphocytes with peptides bound to HLA expressed on the surface of antigen-presenting cells [1,2]. Effective immune surveillance benefits from extensive polymorphism within the HLA genetic region encoding amino acid residues centered in the peptide-binding groove, where diversity expands the overall repertoire of HLA-bound peptide ligands and their respective antigen-specific T cells [2].Letermovir for prevention of cytomegalovirus reactivation in haploidentical and mismatched adult donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide for graft-versus-host disease prophylaxisA. Lin, J. Flynn, L. DeRespiris, B. Figgins, M. Griffin, C. Lau, A. Proli, S.M. Devlin, C. Cho, R. Tamari, A.A. Jakubowski, E.B. Papadopoulos, S.A. Giralt, M.A. Perales, S.K. Seo, B. ShafferDOI: https://doi.org/10.1016/j.bbmt.2020.10.009Publication stage: In Press Journal Pre-ProofPreviewFull-Text HTMLPDFxCytomegalovirus (CMV) is a common viral infection in recipients of allogeneic hematopoietic cell transplantation (allo HCT).1,2 Untreated CMV infection results in significant morbidity and mortality in this population, necessitating the use of pre-emptive anti-viral therapies in patients with detectable viremia.3,4 CMV-active antiviral agents have significant adverse effects including myelosuppression (ganciclovir and valganciclovir), or renal injury (foscarnet), among others, leading to additive toxicities in allo HCT recipients requiring treatment for CMV.The Role of Blood and Marrow Transplantation in Treating Pediatric Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase InhibitorsDelphine Veys, Persis Amrolia, Ajay Vora, Paul Veys, Anupama Rao, Michael GattensDOI: https://doi.org/10.1016/j.bbmt.2020.10.011Publication stage: In Press Corrected ProofPreviewFull-Text HTMLPDFSupplemental MaterialsxThe introduction of tyrosine kinase inhibitors (TKIs) in 2001 revolutionized the treatment of chronic myelogenous leukemia (CML) in adults, largely supplanting blood and marrow transplantation (BMT). Within 5 years, these revolutionary drugs had also been approved for use in pediatric patients with CML. However, due to the low disease incidence and subsequent lack of robust clinical trial data in pediatric CML, the management of pediatric CML is largely extrapolated from adult data. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector CellsDOI: https://doi.org/10.1016/j.bbmt.2018.12.758Biology of Blood and Marrow Transplantation, Vol. 25, Issue 4Open AccessValidation of the Hematopoietic Cell Transplantation–Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell TransplantationDOI: https://doi.org/10.1016/j.bbmt.2017.06.005Biology of Blood and Marrow Transplantation, Vol. 23, Issue 10Open ArchiveClinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R TrialDOI: https://doi.org/10.1016/j.bbmt.2020.09.036Publication stage: In Press Uncorrected ProofBiology of Blood and Marrow TransplantationOpen AccessImaging in Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction SyndromeDOI: https://doi.org/10.1016/j.bbmt.2020.06.016Biology of Blood and Marrow Transplantation, Vol. 26, Issue 10Open AccessGuidelines for COVID-19 Management in Hematopoietic Cell Transplantation and Cellular Therapy RecipientsDOI: https://doi.org/10.1016/j.bbmt.2020.07.027Biology of Blood and Marrow Transplantation, Vol. 26, Issue 11Transplantation Category: 7 of 24 journalsHematology Category: 21 of 76 journals Immunology Category: 61 of 158 journals 2019 Journal Citation Report Clarivate Analytics, 2020 Journal Access Full-text articles are available to ASTCT members and personal subscribers starting from 1998 to the present. Access to abstracts is complimentary. Activate Online Access Access this journal on ScienceDirect Visit ScienceDirect to see if you have access via your institution. About Biology of Blood and Marrow Transplantation Biology of Blood and Marrow Transplantation publishes original research reports, reviews, editorials, commentaries, letters to the editor, and hypotheses and is the official publication of the American Society for Transplantation and Cellular Therapy. The journal focuses on current technology and knowledge in the interdisciplinary field of hematopoetic stem cell transplantation. The American Society for Transplantation and Cellular Therapy is a national professional association that promotes advancement of the field of blood and bone marrow transplantation. ASTCT members are both in clinical practice and in research.

TAGS:Biology of Home 

<<< Thank you for your visit >>>

Hot Websites